Canakinumab in Schnitzler Syndrome
Seminars in Arthritis and Rheumatism, 08/20/2012
Clinical Article
Vanderschueren S et al. – Canakinumab has potential for the treatment of Schnitzler syndrome.
Methods- A patient with Schnitzler syndrome was treated with canakinumab, 150 mg subcutaneously injection every 8 weeks for 6 consecutive months.
- Injections were resumed in case of a flare following discontinuation.
- Canakinumab induced a swift and sustained clinical response, with disappearance of fever and arthralgias, near abolishment of fatigue and rash, and substantial reduction of C-reactive protein levels.
- Interruption of canakinumab after four 8-weekly injections led to a flare 10 weeks after the last administration, which was countered as soon as canakinumab injections were resumed.
- The patient remained in complete remission.
- Canakinumab was well tolerated.
- No injection site reactions, other adverse events, or laboratory abnormalities were observed.
